STOCK TITAN

Millennium affiliates and Israel Englander disclose SUPN 5.7% stakes (SUPN)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Supernus Pharmaceuticals, Inc. Schedule 13G/A reports beneficial ownership disclosures by investment managers and a principal. Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander are each shown with 5.7% of common stock, equivalent to 3,281,615 shares. Integrated Core Strategies (US) LLC is shown with 4.9%, equivalent to 2,817,883 shares. The filing is a joint filing under a February 17, 2026 Joint Filing Agreement.

Positive

  • None.

Negative

  • None.

Insights

Joint disclosure clarifies ownership stakes by managers and a principal.

The filing lists shared voting and dispositive power for Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander at 5.7% (3,281,615 shares) and for Integrated Core Strategies (US) LLC at 4.9% (2,817,883 shares), with voting control described as exercised through entities under Millennium's management.

Ownership is presented as a joint filing under a February 17, 2026 agreement; subsequent filings will show any changes in those percentages.

Disclosure indicates multiple institutional/associated holders near single‑digit stakes.

The filing shows shared dispositive power rather than sole control for the reported positions, which suggests aggregated influence through managed entities. The percentages reported are below typical 10% thresholds used for certain regulatory or strategic signals.

For market impact, changes to these holdings would be observable only if amended forms report different share counts or percent figures; the joint filing date is February 17, 2026.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Integrated Core Strategies (US) LLC
Signature:/s/ Gil Raviv
Name/Title:Gil Raviv, Global General Counsel
Date:02/17/2026
Millennium Management LLC
Signature:/s/ Gil Raviv
Name/Title:Gil Raviv, Global General Counsel
Date:02/17/2026
Millennium Group Management LLC
Signature:/s/ Gil Raviv
Name/Title:Gil Raviv, Global General Counsel
Date:02/17/2026
Israel A. Englander
Signature:/s/ Israel A. Englander
Name/Title:Israel A. Englander
Date:02/17/2026

Comments accompanying signature: ** INTEGRATED CORE STRATEGIES (US) LLC By: Integrated Holding Group LP, its Managing Member By: Millennium Management LLC, its General Partner
Exhibit Information

Exhibit I: Joint Filing Agreement, dated as of February 17, 2026, by and among Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.

FAQ

What stake does Millennium Management report in SUPN?

Millennium Management LLC reports beneficial ownership of 3,281,615 shares, equal to 5.7% of common stock. This figure is shown in the Schedule 13G/A joint filing dated February 17, 2026 and reflects shared voting and dispositive power.

How many shares does Integrated Core Strategies (US) LLC disclose?

Integrated Core Strategies (US) LLC discloses 2,817,883 shares, equal to 4.9% of common stock. The ownership is reported with shared voting and dispositive power in the joint Schedule 13G/A filing.

Is the filing a joint submission for SUPN ownership?

Yes. The excerpt references a Joint Filing Agreement dated February 17, 2026 among Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander, making this a joint Schedule 13G/A.

Does Israel A. Englander report direct ownership in SUPN?

Israel A. Englander is shown with beneficial ownership of 3,281,615 shares (5.7%), reported as shared voting and dispositive power through entities under Millennium's management in the joint filing.

Are the reported positions sole or shared power?

The filing shows shared voting and shared dispositive power for the reported positions; sole voting and dispositive power are listed as 0 for the named filers in the excerpt.
Supernus Pharma

NASDAQ:SUPN

SUPN Rankings

SUPN Latest News

SUPN Latest SEC Filings

SUPN Stock Data

2.96B
54.86M
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
ROCKVILLE